Cargando…

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

Detalles Bibliográficos
Autores principales:	Schöffski, P, Garfield, D H, Hercbergs, A, Wolter, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856006/ https://www.ncbi.nlm.nih.gov/pubmed/20354526 http://dx.doi.org/10.1038/sj.bjc.6605628

Ejemplares similares

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Novello, S, et al.
Publicado: (2010)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study
por: Cortes, Jorge E., et al.
Publicado: (2023)

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
por: Allan, John N., et al.
Publicado: (2021)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Yun, Hwan-Jung, et al.
Publicado: (2015)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
por: Benner, Brooke, et al.
Publicado: (2021)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
por: Kockerols, Camille C.B., et al.
Publicado: (2022)

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
por: Byrgazov, K, et al.
Publicado: (2017)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
por: Chen, Z, et al.
Publicado: (2016)

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
por: Rovithi, Maria, et al.
Publicado: (2017)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
por: Mou, Lisha, et al.
Publicado: (2021)

Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor
por: Nie, Guangyan, et al.
Publicado: (2021)

Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China
por: Chen, Yilin, et al.
Publicado: (2022)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review
por: Din, Mohammad Ammad Ud, et al.
Publicado: (2022)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy
por: Riva, G, et al.
Publicado: (2011)

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer
por: Poliaková, Michaela, et al.
Publicado: (2018)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea
por: Kong, Jee Hyun, et al.
Publicado: (2022)

Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19
por: Rezaei, Mitra, et al.
Publicado: (2020)

Safety of ustekinumab in adolescent patients with moderate‐to‐severe plaque psoriasis: real‐world evidence from an ongoing European study (NCT03218488)
por: Mahé, E., et al.
Publicado: (2022)

Metformin: Ongoing Journey with Superdrug Revolution
por: EL-Arabey, Amr Ahmed, et al.
Publicado: (2019)

Ongoing green peafowl protection in China
por: Wu, Fei, et al.
Publicado: (2019)

Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitor
por: Wang, Jiayu, et al.
Publicado: (2018)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
por: Yang, Xiaobo, et al.
Publicado: (2022)

Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption
por: Demeter, Judit, et al.
Publicado: (2021)

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015)

X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase
por: Agrebi, Nourhen, et al.
Publicado: (2021)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

BCL2L2 loss renders ‐14q renal cancer dependent on BCL2L1 that mediates resistance to tyrosine kinase inhibitors
por: Lyu, Yinfeng, et al.
Publicado: (2021)

Comments on “Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India”
por: Ghaznavi, Hamid, et al.
Publicado: (2022)

Starting clozapine in patients with schizophrenia during the ongoing pandemic
por: Grover, Sandeep, et al.
Publicado: (2022)

Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors
por: Gee, Julia MW
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_gvpt922mne281m54079i7uil5v